Piramal Pharma expects single-digit growth in FY26 amid uncertainties

Piramal Pharma anticipates a modest financial year in 2026, projecting single-digit growth as it navigates through global uncertainties. The pharmaceutical giant remains cautious yet optimistic, balancing its strategies amid fluctuating market dynamics and geopolitical tensions that could impact the healthcare sector worldwide. Despite the challenges, the company is committed to maintaining its growth trajectory. In response to these uncertainties, Piramal Pharma is focusing on its India consumer health segment, targeting a revenue of Rs 2000 crore. This strategic emphasis on domestic markets aims to mitigate the risks associated with global volatility. By leveraging its strong brand presence and expanding its product offerings, the company seeks to bolster its consumer health division, which has consistently shown resilience and potential for expansion. To achieve these goals, Piramal Pharma plans to invest in innovative solutions and enhance operational efficiencies. The company is exploring partnerships and collaborations to strengthen its market position and drive sustainable growth. As it navigates through these complex times, Piramal Pharma remains committed to delivering value to its stakeholders while adapting to the evolving landscape of the pharmaceutical industry.

— Authored by Next24 Live